Hepatocellular carcinoma surveillance in the 21st century: Saving lives or causing harm?
6
조회
0
다운로드
8
인용
0
참고문헌
키워드
초록
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available if detected at an early stage. However, two thirds of patients with HCC are diagnosed at a late stage and not eligible for cure. Therefore several liver professional societies recommend HCC surveillance using abdominal ultrasound with or without alpha fetoprotein in at-risk populations, including patients with cirrhosis and subsets of those with chronic hepatitis B. Available data suggest HCC surveillance can significantly improve early tumor detection, curative treatment eligibility, and overall survival. However, the potential benefits of HCC surveillance must be considered in light a shifting HCC demographic from a viral-mediated cancer to an increasing proportion of patients having non-alcoholic steatohepatitis, which has been shown to limit ultrasound sensitivity and may mitigate observed benefits. Further, benefits of HCC surveillance must be weighed against potential physical, financial and psychological harms. Continued data for both benefits and harms of HCC surveillance in contemporary populations are necessary. In the interim, providers should continue to strive for high quality HCC surveillance in at-risk patients.
Abstract
Hepatocellular carcinoma (HCC) is the third most common cause of cancer related death worldwide. Prognosis and treatment options largely depend on tumor stage at diagnosis, with curative treatments only available if detected at an early stage. However, two thirds of patients with HCC are diagnosed at a late stage and not eligible for cure. Therefore several liver professional societies recommend HCC surveillance using abdominal ultrasound with or without alpha fetoprotein in at-risk populations, including patients with cirrhosis and subsets of those with chronic hepatitis B. Available data suggest HCC surveillance can significantly improve early tumor detection, curative treatment eligibility, and overall survival. However, the potential benefits of HCC surveillance must be considered in light a shifting HCC demographic from a viral-mediated cancer to an increasing proportion of patients having non-alcoholic steatohepatitis, which has been shown to limit ultrasound sensitivity and may mitigate observed benefits. Further, benefits of HCC surveillance must be weighed against potential physical, financial and psychological harms. Continued data for both benefits and harms of HCC surveillance in contemporary populations are necessary. In the interim, providers should continue to strive for high quality HCC surveillance in at-risk patients.
참고문헌 (34)
- Ferlay J, "Cancer incidence and mortality worldwide : sources, methods and major patters in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~ (2015)[DOI]
- Chiang CJ, "Thirty-year outcomes of the national hepatitis B immunization program in Taiwan", JAMA, 310, pp.974~976 (2013)
- Petrick JL, "International trends in liver cancer incidence, overall and by histologic subtype, 1978-2007", Int J Cancer, 139, pp.1534~1545 (2016)
- Petrick JL, "Future of hepatocellular carcinoma incidence in the United States forecast through 2030", J Clin Oncol, 34, pp.1787~1794 (2016)
- El-Serag HB, "Hepatocellular carcinoma", N Engl J Med, 365, pp.1118~1127 (2011)
- Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- European Association for the Study of the Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Omata M, "Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma : a 2017 update", Hepatol Int, 11, pp.317~370 (2017)
- ")—health professional version"[URL]
- Rich NE, "Overdiagnosis : an understudied issue in hepatocellular carcinoma surveillance", Semin Liver Dis, 37, pp.296~304 (2017)
- Zhang BH, "Randomized controlled trial of screening for hepatocellular carcinoma", J Cancer Res Clin Oncol, 130, pp.417~422 (2004)
- Kansagara D, "Screening for hepatocellular carcinoma in chronic liver disease : a systematic review", Ann Intern Med, 161, pp.261~269 (2014)
- Singal AG, "Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis : a meta-analysis", PLoS Med, 11, pp.e1001624~ (2014)
- Choi DT, "Hepatocellular carcinoma screening is associated with increased survival of patients with cirrhosis", Clin Gastroenterol Hepatol, 17, pp.976~987 (2019)[DOI]
- Moon AM, "No association between screening for hepatocellular carcinoma and reduced cancer-related mortality in patients with cirrhosis", Gastroenterology, 155, pp.1128~1139 (2018)[DOI]
- Atiq O, "An assessment of benefits and harms of hepatocellular carcinoma surveillance in patients with cirrhosis", Hepatology, 65, pp.1196~1205 (2017)
- Konerman MA, "Frequency and outcomes of abnormal imaging in patients with cirrhosis enrolled in a hepatocellular carcinoma surveillance program", Liver Transpl, 25, pp.369~379 (2019)
- Naimark D, "The meaning of life expectancy : what is a clinically significant gain", J Gen Intern Med, 9, pp.702~707 (1994)
- Sarasin FP, "Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis", Am J Med, 101, pp.422~434 (1996)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- Andersson KL, "Cost effectiveness of alternative surveillance strategies for hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 6, pp.1418~1424 (2008)
- Patel D, "Cost-effectiveness of hepatocellular carcinoma surveillance in patients with hepatitis C virus-related cirrhosis", Clin Gastroenterol Hepatol, 3, pp.75~84 (2005)
- Tzartzeva K, "Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis : a meta-analysis", Gastroenterology, 154, pp.1706~1718 (2018)[DOI]
- Simmons O, "Predictors of adequate ultrasound quality for hepatocellular carcinoma surveillance in patients with cirrhosis", Aliment Pharmacol Ther, 45, pp.169~177 (2017)
- Del Poggio P, "Factors that affect efficacy of ultrasound surveillance for early stage hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 12, pp.1927~1933 (2014)[DOI]
- Gopal P, "Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis", Clin Gastroenterol Hepatol, 12, pp.870~877 (2014)
- Lee E, "Improving screening for hepatocellular carcinoma by incorporating data on levels of α-fetoprotein, over time", Clin Gastroenterol Hepatol, 11, pp.437~440 (2013)
- Tayob N, "Validation of the hepatocellular carcinoma early detection screening(HES)algorithm in a cohort of veterans with cirrhosis", Clin Gastroenterol Hepatol, 17, pp.1886~1893 (2019)[DOI]
- Chaiteerakij R, "Update on biomarkers of hepatocellular carcinoma", Clin Gastroenterol Hepatol, 13, pp.237~245 (2015)
- Davila JA, "Use of surveillance for hepatocellular carcinoma among patients with cirrhosis in the United States", Hepatology, 52, pp.132~141 (2010)
- Beste LA, "Improved surveillance for hepatocellular carcinoma with a primary care-oriented clinical reminder", Clin Gastroenterol Hepatol, 13, pp.172~179 (2015)
- Singal AG, "Mailed outreach invitations significantly improve HCC surveillance rates in patients with cirrhosis : a randomized clinical trial", Hepatology, 69, pp.121~130 (2019)
- Taylor EJ, "Modeling the benefits and harms of surveillance for hepatocellular carcinoma : information to support informed choices", Hepatology, 66, pp.1546~1555 (2017)